K Number
K253406

Validate with FDA (Live)

Date Cleared
2026-03-25

(176 days)

Product Code
Regulation Number
892.5050
Age Range
0.083 - 100
Reference & Predicate Devices
Predicate For
N/A
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticPediatricDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The MEVION S250-FIT is intended to deliver proton radiation treatment to patients with localized tumors or any other conditions susceptible to treatment by radiation. When the patient is in the fully seated position, the MEVION S250-FIT is indicated for treatment of patients with localized tumors and other conditions susceptible to treatment by radiation in the sites above the mid-chest or carina.

Device Description

The S250-FIT Proton Beam Radiation Therapy Device is a proton beam radiation therapy system that provides a therapeutic proton beam for clinical treatment. It is designed to deliver a proton beam with the prescribed dose and three-dimensional dose distribution to the prescribed patient treatment site. The MEVION S250-FIT delivers radiation via a pencil beam (spot) scanning modality. In order to reach a target depth of 32cm in the patient, the accelerator is designed to produce a 230MeV beam.

This submission incorporates an optional subsystem for 2D image verification using oblique x-rays to verify patient alignment prior to beam delivery.

The S250-FIT is comprised of the following subsystems:

  • Beam Generation System – generates the beam and directs it to the beam delivery system.
  • Beam Delivery System – ensures that the therapeutic prescription parameters are properly delivered.
  • Hardwired Safety System (HSS) – provides for system and beam delivery interlocking without the use of software
  • Patient Positioning System – The Marie Device from Leo Cancer Care (K250970) allows for accurate and efficient positioning of the patient in a seated or perched position for treatment using an Upright Patient Positioner and 3D CT Scanner for Treatment Planning and Patient Registration.
  • Structural Support/Alignment System – supports the beam generation and delivery systems and allows the fixed beam delivery to the single point in space (i.e., the Isocenter)
  • System Software – controls the above subsystems (except the HSS) and provides interfaces to the system for the end-user.
  • Verification Imaging Subsystem (Optional) – 2D Oblique X-ray System that provides a secondary means of verification for patient alignment to the end-user. A separate software package, Verity is used to generate a 3D reconstruction and displays images for alignment.
AI/ML Overview

N/A

FDA 510(k) Clearance Letter - S250-FIT Proton Beam Radiation Therapy Device

Page 1

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

Doc ID # 04017.08.04

March 25, 2026

Mevion Medical Systems, Inc.
Jason Brown
Director, Quality and Regulatory Affairs
300 Foster St.
Littleton, Massachusetts 01460

Re: K253406
Trade/Device Name: S250-FIT Proton Beam Radiation Therapy Device
Regulation Number: 21 CFR 892.5050
Regulation Name: Medical Charged-Particle Radiation Therapy System
Regulatory Class: Class II
Product Code: LHN
Dated: October 23, 2025
Received: October 23, 2025

Dear Jason Brown:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Page 2

K253406 - Jason Brown
Page 2

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-

Page 3

K253406 - Jason Brown
Page 3

assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Lora D. Weidner, Ph.D.
Assistant Director
Radiation Therapy Team
DHT8C: Division of Radiological
Imaging and Radiation Therapy Devices
OHT8: Office of Radiological Health
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Page 4

Indications for Use

Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions.
K253406

Please provide the device trade name(s).
S250-FIT Proton Beam Radiation Therapy Device

Please provide your Indications for Use below.
The MEVION S250-FIT is intended to deliver proton radiation treatment to patients with localized tumors or any other conditions susceptible to treatment by radiation. When the patient is in the fully seated position, the MEVION S250-FIT is indicated for treatment of patients with localized tumors and other conditions susceptible to treatment by radiation in the sites above the mid-chest or carina.

Please select the types of uses (select one or both, as applicable).
☑ Prescription Use (Part 21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C)

Page 5

Traditional 510(k) Summary

K# K253406
Page 1 of 7

Mevion Medical Systems Inc.

Mevion S250-FIT Proton Beam Radiation Therapy Device

I. Submitter

Mevion Medical Systems Inc.
300 Foster St
Littleton, MA 01460
USA

Contact:
Jason Brown
Jason.Brown@Mevion.com

510(k) Number: K253406
Date: September 30, 2025

II. Device

Device Trade Name: S250-FIT Proton Beam Radiation Therapy Device
Product Classification: Class II
Common Name: Medical charged-particle radiation therapy system
Classification Name: System, Radiation Therapy, Charged-Particle, Medical
Regulation Number: 892.5050
Product Code: LHN

III. Predicate Device

Predicate Device: S250-FIT Proton Beam Radiation Therapy Device (K250986)
Regulation Number: 892.5050
Product Code: LHN

Page 6

K# K253406
Page 2 of 7

This 510(k) is a modification of the Mevion Medical Systems previously cleared device to incorporate an optional 2D Image Verification Subsystem.

IV. Indications for Use

The MEVION S250-FIT Proton Beam Radiation Therapy Device is intended to deliver proton radiation treatment to patients with localized tumors or any other conditions susceptible to treatment by radiation. When the patient is in the fully seated position, the MEVION S250-FIT is indicated for treatment of patients with localized tumors and other conditions susceptible to treatment by radiation in the sites above the mid-chest or carina.

V. Device Description

The S250-FIT Proton Beam Radiation Therapy Device is a proton beam radiation therapy system that provides a therapeutic proton beam for clinical treatment. It is designed to deliver a proton beam with the prescribed dose and three-dimensional dose distribution to the prescribed patient treatment site. The MEVION S250-FIT delivers radiation via a pencil beam (spot) scanning modality. In order to reach a target depth of 32cm in the patient, the accelerator is designed to produce a 230MeV beam.

This submission incorporates an optional subsystem for 2D image verification using oblique x-rays to verify patient alignment prior to beam delivery.

The S250-FIT is comprised of the following subsystems:

  • Beam Generation System – generates the beam and directs it to the beam delivery system.
  • Beam Delivery System – ensures that the therapeutic prescription parameters are properly delivered.
  • Hardwired Safety System (HSS) – provides for system and beam delivery interlocking without the use of software
  • Patient Positioning System – The Marie Device from Leo Cancer Care (K250970) allows for accurate and efficient positioning of the patient in a seated or perched position for treatment using an Upright Patient Positioner and 3D CT Scanner for Treatment Planning and Patient Registration.
  • Structural Support/Alignment System – supports the beam generation and delivery systems and allows the fixed beam delivery to the single point in space (i.e., the Isocenter)
  • System Software – controls the above subsystems (except the HSS) and provides interfaces to the system for the end-user.

Page 7

K# K253406
Page 3 of 7

  • Verification Imaging Subsystem (Optional) – 2D Oblique X-ray System that provides a secondary means of verification for patient alignment to the end-user. A separate software package, Verity is used to generate a 3D reconstruction and displays images for alignment.

VI. Comparison of Technological Characteristics with the Predicate

The Subject device is substantially equivalent to the previously cleared predicate device. Both systems provide a therapeutic proton beam for clinical treatment and have the same indications for use. The Subject device incorporates an optional 2D Verification Imaging System to be used to verify patient alignment prior to delivering treatment. This difference does not raise questions of safety or effectiveness and testing demonstrates substantially equivalent performance compared to the predicate.

A table comparing the key features of the subject and predicate devices is provided below.

Device FeatureSubject DevicePredicate DeviceSE Comparison
Trade NameS250-FIT Proton Beam Radiation Therapy DeviceS250-FIT Proton Beam Radiation Therapy Device-
ManufacturerMevion Medical Systems, Inc.Mevion Medical Systems, Inc.-
510(k)K253406K250986-

Page 8

K# K253406
Page 4 of 7

Device FeatureSubject DevicePredicate DeviceSE Comparison
Intended Use/ IndicationsThe MEVION S250-FIT Proton Beam Radiation Therapy Device is intended to deliver proton radiation treatment to patients with localized tumors or any other conditions susceptible to treatment by radiation. When the patient is in the fully seated position, the MEVION S250-FIT is indicated for treatment of patients with localized tumors and other conditions susceptible to treatment by radiation in the sites above the mid-chest or carina.The MEVION S250-FIT Proton Beam Radiation Therapy Device is intended to deliver proton radiation treatment to patients with localized tumors or any other conditions susceptible to treatment by radiation. When the patient is in the fully seated position, the MEVION S250-FIT is indicated for treatment of patients with localized tumors and other conditions susceptible to treatment by radiation in the sites above the mid-chest or carina.The subject device and predicate device are identical
Patient PopulationAdults, PediatricsAdults, PediatricsThe subject device and predicate device are identical
Proton Accelerator230 MeV superconducting synchrocyclotron230 MeV superconducting synchrocyclotronThe subject device and predicate device are identical
Usable Energy Range30 - 230 MeV30 - 230 MeVThe subject device and predicate device are identical
Beam Delivery ModalityPencil Beam ScanningPencil Beam ScanningThe subject device and predicate device are identical
Beam Range in patient0.8 g/cm² – 32.2 g/cm²0.8 g/cm² – 32.2 g/cm²The subject device and predicate device are identical
Dose Rate2Gy/Min2Gy/MinThe subject device and predicate device are identical
Spot Distal Dose FalloffThe 80% - 20% distal dose falloff of any pristine Bragg peak in water is 0.5 cm or lessThe 80% - 20% distal dose falloff of any pristine Bragg peak in water is 0.5 cm or lessThe subject device and predicate device are identical

Page 9

K# K253406
Page 5 of 7

Device FeatureSubject DevicePredicate DeviceSE Comparison
Beam Spot Size≤ 0.5 cm for maximum energy (depth) and no greater than 1.5 cm for minimum energy (depth)≤ 0.5 cm for maximum energy (depth) and no greater than 1.5 cm for minimum energy (depth)The subject device and predicate device are identical
Spot Range AccuracyWithin ± 0.1 g/cm² over all operational parameters of the system.Within ± 0.1 g/cm² over all operational parameters of the system.The subject device and predicate device are identical.
Range SelectionBoron-carbide ceramic Range Shifter PlatesBoron-carbide ceramic Range Shifter PlatesThe subject device and predicate device are identical
Energy ModulationBoron-carbide ceramic Range Shifter PlatesBoron-carbide ceramic Range Shifter PlatesThe subject device and predicate device are identical
Patient Positioner6-axis Platform Mounted Upright Positioner6-axis Platform Mounted Upright PositionerThe subject device and predicate device are identical
Maximum Load330 lbs330 lbsThe subject device and predicate device are identical
Imaging (3D)Integrated CT supplied by Leo Cancer Care, ltd.Integrated CT supplied by Leo Cancer Care, ltd.The subject device and predicate device are identical.
Imaging (2D) (Optional)2D Oblique X-Ray System supplied by Mevion Medical Systems, inc.-The subject device includes an optional subsystem that allows for secondary verification imaging for patient positioning. The primary method of verification prior to treatment remains unchanged and the new 2D Imaging Option does not allow for the application of deltas to the UPP. The addition of this subsystem does not impact intended use or treatment, and does not raise new questions of safety or effectiveness.

Page 10

K# K253406
Page 6 of 7

Device FeatureSubject DevicePredicate DeviceSE Comparison
Discrete Arc PlanningYesYesThe subject device and predicate device are identical.
Remote MotionYesYesThe subject device and predicate device are identical.

VII. Summary of Performance Testing (Non-Clinical)

Verification testing was performed to address aspects of the device design that have changed or that may have been impacted by the changes to the device design.

Standards Testing was completed in accordance with the following FDA-recognized standards:

Basic Electrical Safety and EMC

  • IEC 60601-1 Edition 3.2 2020-08 CONSOLIDATED VERSION, Medical electrical equipment - Part 1: General requirements for basic safety and essential performance
  • IEC 60601-1-2:2020 Medical electrical equipment - Part 1: General requirements for basic safety and essential performance

X-Ray/CT

  • IEC 60601-2-68:2014 Particular requirements for the basic safety and essential performance of X-ray-based image-guided radiotherapy equipment for use with electron accelerators, light ion beam therapy equipment and radionuclide beam therapy equipment
  • IEC 60601-1-3 Edition 2.2 2021-01 CONSOLIDATED VERSION General Requirements for radiation protection in diagnostic x-ray equipment
  • IEC 60601-2-54 Edition 2.0 2022-09 Medical electrical equipment - Part 2-54: Particular requirements for the basic safety and essential performance of X-ray equipment for radiography and radioscopy

Lasers

  • IEC 60825-1 Edition 3, Safety of Laser Products – Part 1 Equipment Classification and Requirements

Page 11

K# K253406
Page 7 of 7

Cybersecurity testing was conducted in accordance with ANSI/AAMI SW96:2023 and follow FDA Draft Guidance Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions Draft Guidance for Industry and Food and Drug Administration Staff, Issued April 8, 2022.

Software development and testing was performed in accordance with IEC 62304 Edition 1.1 2015-06 and FDA Guidance Document, Content of Premarket Submissions for Device Software Functions - Guidance for Industry and Food and Drug Administration Staff, Issued June 14, 2023.

Human Factors and Usability Testing was conducted according to IEC 62366-1:2015+A1:2020, IEC 60601-1-6 Edition 3.2 2020-07, FDA Guidance, Applying Human Factors and Usability Engineering to Medical Devices - Guidance for Industry and Food and Drug Administration Staff, Issued February 2016 and FDA Draft Guidance, Content of Human Factors Information in Medical Device Marketing Submissions.

Clinical Testing

  • Not applicable.

VIII. Substantial Equivalence Conclusion

The S250-FIT Proton Beam Radiation Therapy Device is substantially equivalent to the previously cleared S250-FIT Proton Beam Radiation Therapy Device. The Subject device and the predicate have the same intended use and differences between the systems do not raise new questions of safety or effectiveness. Therefore, the S250-FIT Proton Beam Radiation Therapy Device is substantially equivalent.

§ 892.5050 Medical charged-particle radiation therapy system.

(a)
Identification. A medical charged-particle radiation therapy system is a device that produces by acceleration high energy charged particles (e.g., electrons and protons) intended for use in radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories.(b)
Classification. Class II. When intended for use as a quality control system, the film dosimetry system (film scanning system) included as an accessory to the device described in paragraph (a) of this section, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.